Biotechnology intellectual property & prior therapeutic research
Trafalgar International, Inc.'s historical operations, conducted under the former name Greater Cannabis Company, Inc., produced biotechnology intellectual property, therapeutic development assets, scientific relationships, and research initiatives that remain part of the Company's business foundation. The Company intends to continue evaluating appropriate pathways for those assets, including internal development, licensing, strategic collaboration, joint ventures, and other commercial arrangements.
GCANRx's Combined Therapeutic Approach to Treating ASD
Groundbreaking ASD Research
In 2017, Dr. Adi Aran conducted the world's most comprehensive study on the effects of CBD oil on children with autism. It was also the first double-blind placebo-controlled trial of its kind. The results of the study were encouraging, with 49% of one group reporting an improvement in disruptive behavior. But it was also clear that there was a need for follow up research.
Compelling Follow Up Study
In 2019, a second study focused on children diagnosed with ASD, which was also characterized by severe behavior disturbance. The results of this study also showed a positive correlation between CBD and reduced symptoms:
Reported much improved or very much improved behavioral outbursts
Showed improvement of communication problems
Reported reduced anxiety
Improvement in disruptive behaviors
Parents reported less stress on average
Greater Results With Combined Treatment
In addition to CBD, proprietary compounds have demonstrated particular efficacy for treating ASD associated symptoms in preliminary trials. Each of these compounds on their own demonstrated limited efficacy, which is attributed to the highly complex nature of ASD. A combined treatment with these compounds can lead to a significantly greater reduction of disruptive behavior and core autistic symptoms while limiting side effects.
Phase II Clinical Trial
GCANRx has teamed up with a world renowned research center to treat 100 children diagnosed with ASD and related behavioral problems, with a combination of CBD, and additional proprietary compounds for up to 24 weeks.
First Study of its Kind
combining proven CBD with empirically supported therapeutic compounds
Substantiated by Pre-Clinical Trial
as well as anecdotal and predecessor clinical results
Conducted by Leading Researcher
in the field with a proven track record of results
Combination of Compounds
ensures the uniqueness of the study and patentability of its results
Technology portfolio pathways
Trafalgar International, Inc. may pursue multiple pathways for the development and monetization of its current and future intellectual property, depending on market conditions, available resources, strategic fit, and commercial potential.